There's never been a successful Rx mutation-directed pill approved for brain cancer (gliomas and astrocytomas, grade 2) that extends progression-free survival, until the one directed vs IDH mutations came along. Unfortunately, its price is $480K/year https://
statnews.com/2024/09/13/vor
anigo-servier-brain-cancer-breakthrough/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-9DWCCc1Ks1m4ePfKrA9eh5KuIbxXyRQ6Z8kJbcMA1R_X2AF0P3L8-bZ_ZErbz7UnVirnkrwg4a01d4C2k1RSYLVARWlg&_hsmi=324444687&utm_content=324444687&utm_source=hs_email
…

→ View original post on X — @erictopol,